Merit Medical signs $22M asset deal to acquire C2 CryoBalloon from PENTAX Medical

MERIT MEDICAL SYSTEMS INC

Total consideration $22M: $19M cash at closing plus up to $3M in milestone payments.
Closing expected Q4 2025, subject to customary conditions.
Projected 2026 revenue $6-8M; non-GAAP EPS dilution $0.02-0.03 in 2026, accretive thereafter.
Expands Merit's Endoscopy portfolio targeting Barrett's esophagus and GERD.
PENTAX employees expected to join Merit; manufacturing to transfer to South Jordan, UT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.